AbbVie Ventures News and Activities

AbbVie Ventures is owned by AbbVie.

AbbVie is one of the...

• Forbes Global 2000 (#108);
• Fortune 500 (#77);
• Global Fortune 500 (#249);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

AbbVie is a company listed under the stock ticker ABBV (US).

AbbVie has a direct presence in 20 countries.

AbbVie has 26 subsidiaries including AbbVie APAC, AbbVie Australia and AbbVie Belgium.

They are in:

• Pharmaceuticals89%
• Biotechnology7%
• Other4%

Acquisition, funding and merger involving AbbVie.

• AbbVie has announced the acquisition of Kestrel Therapeutics  (posted on April 29 2026).
• Capstan Therapeutics and AbbVie have merged  (posted on August 19 2025)..
• AbbVie has announced the acquisition of Capstan Therapeutics  (posted on July 1 2025).
• AbbVie has acquired Cerevel Therapeutics (posted on August 5 2024).
• See more news about AbbVie Hide news involving AbbVie

View the org chart displaying its 7 main executives

Most searched biographies at AbbVie Ventures

• Christian Schubert, Chief Executive Officer
• Shawna Frazier, Director, San Francisco
• Claire Leurent, Managing Director of Cambridge

Popular executive movements at AbbVie

• Dina Gofis has joined the company as Director Business Human Resources, Us Specialty Commercial  (posted on November 11 2025).
• Greg Miley, Senior Vice President, Government Affairs, has left the company  (posted on October 23 2025).

Create your alert
to follow the executive moves at AbbVie Ventures.

AbbVie has 1,642 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).
• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director at KKR

Learn more about the Fund industry

Press releases by AbbVie Ventures

• AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
• U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
• Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
• AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
• AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
• AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• AbbVie News Center - NewsBack ButtonSearch IconFilter Icon
• AbbVie to Present at the Bank of America Securities Healthcare Conference
• Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
• AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
• View more press releases Close

Social media about AbbVie Ventures

• AbbVie Ventures on Wikipedia, Google News & Yahoo Finance
• AbbVie Ventures on LinkedIn, X (Twitter) & YouTube